Distinguishing Lewy body dementias from Alzheimer's disease (Q36998833)

17 August 2017

1 reference

title

Distinguishing Lewy body dementias from Alzheimer's disease (English)

1 reference

17 August 2017

0 references

Rawan Tarawneh

0 references

James E Galvin

1 reference

17 August 2017

publication date

1 November 2007

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

17 August 2017

published in

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

page(s)

1499-1516

1 reference

Clinical phenotype of Parkinson disease dementia

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Risk of dementia in Parkinson's disease: a community-based, prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Synucleinopathies: clinical and pathological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Verbal and visuospatial deficits in dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

What contributes to quality of life in patients with Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Cerebrospinal fluid biomarkers in Alzheimer disease: a fractional improvement?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Personality change precedes clinical diagnosis of dementia of the Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Neuroleptic sensitivity in patients with senile dementia of Lewy body type

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

The progression of cognition, psychiatric symptoms, and functional abilities in dementia with Lewy bodies and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Can alzheimer's disease and dementias with Lewy bodies be distinguished clinically?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Cortical Lewy body dementia: clinical features and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Three years survival in patients with a clinical diagnosis of dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

What best differentiates Lewy body from Alzheimer's disease in early-stage dementia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

The course of psychopathologic features in mild to moderate Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Clinical and neuropathological findings in Lewy body dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Neuropsychological deficits associated with diffuse Lewy body disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Frontotemporal dementia and Alzheimer's disease: retrospective differentiation using information from informants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Novel applications of social-personality measures to the study of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

The differential impacts of Alzheimer's dementia, head injury, and stroke on personality dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Personality traits distinguishing dementia with Lewy bodies from Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Clinical overview of the synucleinopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Cognitive status correlates with neuropathologic stage in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Neurochemical markers do not correlate with cognitive decline in the Lewy body variant of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Nicotinic acetylcholine receptor immunohistochemistry in Alzheimer's disease and dementia with Lewy bodies: differential neuronal and astroglial pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Visual hallucinations are associated with lower alpha bungarotoxin binding in dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

The cell biology of Alzheimer's disease: uncovering the secrets of secretases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Alzheimer's disease-like neuropathology of gene-targeted APP-SLxPS1mut mice expressing the amyloid precursor protein at endogenous levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Disease-modifying therapies in Alzheimer's disease: how far have we come?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Conformational changes of the amyloid beta-peptide (1-40) adsorbed on solid surfaces.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Amyloid &#946;-Peptide [1-42]-Associated Free Radical-Induced Oxidative Stress And Neurodegeneration in Alzheimers Disease Brain: Mechanisms and Consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Deposition of beta-amyloid subtypes 40 and 42 differentiates dementia with Lewy bodies from Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Abeta-42 deposition precedes other changes in PS-1 Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

The alpha-synuclein mutation E46K promotes aggregation in cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

What does it mean to be natively unfolded?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

alpha-Synuclein locus triplication causes Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Mapping of a gene for Parkinson's disease to chromosome 4q21-q23

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Parkinson's disease: piecing together a genetic jigsaw

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Hereditary early-onset Parkinson's disease caused by mutations in PINK1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Lewy body and Alzheimer pathology in a family with the amyloid-beta precursor protein APP717 gene mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

APOE genotype and cholesterol levels in lewy body dementia and Alzheimer disease: investigating genotype-phenotype effect on disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Very low density lipoprotein receptor in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Alzheimer disease: lack of effect of lecithin treatment for 3 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Intralaminar Neurochemical Distributions in Human Midtemporal Cortex: Comparison Between Alzheimer's Disease and the Normal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer's disease: a case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Pharmacotherapy of dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Hallucinations predict attentional improvements with rivastigmine in dementia with lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Inhibition of toxicity in the beta-amyloid peptide fragment beta -(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease - implications for a new therapeutic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Interaction of amyloid binding alcohol dehydrogenase/Abeta mediates up-regulation of peroxiredoxin II in the brains of Alzheimer's disease patients and a transgenic Alzheimer's disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Expression of scavenger receptor class B, type I, by astrocytes and vascular smooth muscle cells in normal adult mouse and human brain and in Alzheimer's disease brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Alpha-tocopherol: roles in prevention and therapy of human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Preformed beta-amyloid fibrils are destabilized by coenzyme Q10 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Compounds that bind APP and inhibit Abeta processing in vitro suggest a novel approach to Alzheimer disease therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

alpha-synuclein gene haplotypes are associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1499

10.1586/14737175.7.11.1499

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference